An overview of the VISTA trial: Newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation

Immunotherapy

Volumn 3, Issue 9, 2011, Pages 1033-1040

  Spicka, Ivan ^d   Mateos, M V ^a   Redman, K ^b   Dimopoulos, M A ^c   Richardson, P G ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

bortezomib; multiple myeloma; peripheral neuropathy; proteasome inhibition; treatment naive older patients

Indexed keywords

BORTEZOMIB; CORTICOSTEROID; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

AGED; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG RESPONSE; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEURALGIA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES;

EID: 80053032099     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.104     Document Type: Review

References (32)

1. Ludwig H, Fritz E, Friedl HP. Epidemiologic and age-dependent data on multiple myeloma in Austria. J. Natl Cancer Inst. 68, 729-733 (1982). (Pubitemid 12070926)
2. Ludwig H, Durie B, Bolejack V et al. Myeloma in patients under age 50 presents with more favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma Working Group. Blood 111, 4039-4047 (2008).
3. Laubach JP, Mitsiades CS, Mahindra A et al. Novel therapies in the treatment of multiple myeloma. J. Natl Compr. Canc. Netw. 7(9), 947-960 (2009).
4. Rosiñol L, Oriol A, Mateos MV et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J. Clin. Oncol. 25(28), 4452-4458 (2007). (Pubitemid 350013852)
5. Laubach JP, Richardson PG, Anderson KC. The evolution and impact of therapy in multiple myeloma. Med. Oncol. 27(Suppl. 1), S1-S6 (2010).
6. Richardson PG, Barlogie B, Berenson J et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348, 2609-2617 (2003). (Pubitemid 36741588)
7. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498 (2005). (Pubitemid 41007864)
8. Mitsiades N, Mitsiades CS, Richardson PG et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377-2380 (2003). (Pubitemid 36302084)
9. Richardson PG, Mitsiades C, Schlossman R et al. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev. Anticancer Ther. 8, 1053-1107 (2008).
10. Berenson JR, Yang HH, Sadler K et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 24, 937-944 (2006). (Pubitemid 46638848)
11. Mateos MV, Hernandez JM, Hernandez MT et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter Phase 1/2 study. Blood 108, 2165-2172 (2006).
12. San Miguel JF, Schlag R, Khuageva NK et al.; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359(9), 906-917 (2008).
13. Bladé J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. 102(5), 1115-1123 (1998). (Pubitemid 28435189)
14. Dimopoulos MA, Richardson PG, Schlag R et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the Phase III VISTA study. J. Clin. Oncol. 27(36), 6086-6093 (2009).
15. Delforge M, Terpos E, Richardson PG et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the Phase III VISTA trial in multiple myeloma. Eur. J. Haematol. 86(5), 372-384 (2011).
16. Mateos MV, Richardson PG, Schlag R et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the Phase III VISTA trial. J. Clin. Oncol. 28(13), 2259-2266 (2010).
17. Dimopoulos MA, Mateos MV, Richardson PG et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan- prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the Phase 3 VISTA study. Eur. J. Haematol. 86(1), 23-31 (2011).
18. Favis R, Sun Y, van de Velde H et al. Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet. Genomics 21(3), 121-129 (2011).
19. Richardson PG, Sonneveld P, Schuster M et al. Extended follow-up of a Phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110(10), 3557-3560 (2007). (Pubitemid 350159621)
20. Giralt S, Stadtmauer EA, Harousseau JL et al.International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).Leukemia 23(10), 1904-1912 (2009).
21. Kumar A, Hozo I, Wheatley K, Djulbegovic B. Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. Am. J. Hematol. 86(1), 18-24 (2011).
22. Harousseau JL, Palumbo A, Richardson P et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy: analysis of the Phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 116(19), 3743-3750 (2010).
23. Sonneveld P, Jongen JL. Dealing with neuropathy in plasma-cell dyscrasias. Hematol. Am. Soc. Hematol. Educ. Program. 2010, 423-430 (2010).
24. Cavo M, Tacchetti P, Patriarca F et al.; GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: A randomised Phase 3 study. Lancet 376(9758), 2075-2085 (2010).
25. Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br. J. Haematol. 152(4), 367-379 (2011).
26. San-Miguel JF, Richardson P, Sonneveld P. Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX Trial. Blood 106, 366 (2005).
27. Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 95, 311-319 (2010).
28. Palumbo A, Bringhen S, Rossi D et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J. Clin. Oncol. 28(34), 5101-5109 (2010).
29. Mateos MV, Oriol A, Martinez-López J et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial. Lancet Oncol. 11(10), 934-941 (2010).
30. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513), 825-831 (2006). (Pubitemid 43363369)
31. Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370(9594), 1209-1218 (2007). (Pubitemid 47516593)
32. Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11(1), 29-37 (2010).